Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients

By Nagourney R.A.   Brewer C.A.   Radecki S.   Kidder W.A.   Sommers B.L.   Evans S.S.   Minor D.R.   DiSaia P.J.  

Gynecologic Oncology, Vol. 88, Iss. 1, 2003-01 ,pp. : 35-39

Academic Press

Access to resources Recommend Favorite

Phase II Trial of Epirubicin at Standard Dose in Relapsed Ovarian Cancer

By Pelaez I.   Lacave A.J.   Palacio I.   Alvarez E.   Cueva J.F.   Muniz I.   Arranz F.   Fra J.  

European Journal of Cancer, Vol. 32, Iss. 5, 1996-05 ,pp. : 899-900

Elsevier

Access to resources Recommend Favorite

Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer

By Larkin J.M.G.   Gore M.E.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 205-216

Adis International

Access to resources Recommend Favorite

Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer

By Burger R.A.   DiSaia P.J.   Roberts J.A.   O'Rourke M.   Gershenson D.M.   Homesley H.D.   Lichtman S.M.   Barnes W.   Moore D.H.   Monk B.J.  

Gynecologic Oncology, Vol. 72, Iss. 2, 1999-02 ,pp. : 148-153

Elsevier

Access to resources Recommend Favorite

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

By Gore M.   Oza A.   Rustin G.   Malfetano J.   Calvert H.   Clarke-Pearson D.   Carmichael J.   Ross G.   Beckman R.A.   Fields S.Z.  

European Journal of Cancer, Vol. 38, Iss. 1, 2002-01 ,pp. : 57-63

Elsevier

Access to resources Recommend Favorite